GNF-Pf-5149

ID: ALA600309

Chembl Id: CHEMBL600309

PubChem CID: 3238689

Max Phase: Preclinical

Molecular Formula: C15H20N4O4

Molecular Weight: 320.35

Molecule Type: Small molecule

Names and Identifiers

Synonyms: GNF-Pf-5149 | MLS000092014|GNF-Pf-5149|SMR000026538|ethyl 6-[5-(1H-imidazol-1-ylmethyl)-2-oxo-2,3-dihydro-1H-imidazol-4-yl]-6-oxohexanoate|CHEMBL600309|BDBM87397|cid_3238689|HMS2331P23|AKOS001788220|CCG-131244|ethyl 6-[5-(imidazol-1-ylmethyl)-2-oxo-1,3-dihydroimidazol-4-yl]-6-oxohexanoate|SR-01000095752|SR-01000095752-1|6-[5-(1-imidazolylmethyl)-2-oxo-1,3-dihydroimidazol-4-yl]-6-oxohexanoic acid ethyl ester|6-[5-(imidazol-1-ylmethyl)-2-keto-4-imidazolin-4-yl]-6-keto-hexanoic acid ethyl ester|ethShow More⌵

Canonical SMILES:  CCOC(=O)CCCCC(=O)c1[nH]c(=O)[nH]c1Cn1ccnc1

Standard InChI:  InChI=1S/C15H20N4O4/c1-2-23-13(21)6-4-3-5-12(20)14-11(17-15(22)18-14)9-19-8-7-16-10-19/h7-8,10H,2-6,9H2,1H3,(H2,17,18,22)

Standard InChI Key:  JHJVVGOEHXTQMZ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA600309

   Ethyl 6-[5-(imidazol-1-ylmethyl)-2-oxo-1,3-dihydroimidazol-4-yl]-6-oxohexanoate

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 320.35

Molecular Weight (Monoisotopic): 320.1485

AlogP: 1.25

#Rotatable Bonds: 9

Polar Surface Area: 109.84

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.14

CX Basic pKa: 6.74

CX LogP: 0.56

CX LogD: 0.49

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.41

Np Likeness Score: -0.75

References

1. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrián F, Matzen JT, Anderson P, Nam TG, Gray NS, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA..  (2008)  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,  105  (26): [PMID:18579783] [10.1073/pnas.0802982105]

2. PubChem BioAssay data set, 

3. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA..  (2011)  Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,  334  (6061): [PMID:22096101] [10.1126/science.1211936]

Source

Source(2):

• Novartis Malaria Screening
• PubChem BioAssays